These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36297659)

  • 41. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles.
    Ibarra LE; Camorani S; Agnello L; Pedone E; Pirone L; Chesta CA; Palacios RE; Fedele M; Cerchia L
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
    Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
    Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimization of Short RNA Aptamers for TNBC Cell Targeting.
    Camorani S; d'Argenio A; Agnello L; Nilo R; Zannetti A; Ibarra LE; Fedele M; Cerchia L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and
    Guo W; Gao H; Li H; Ge S; Zhang F; Wang L; Shi H; Han A
    ACS Appl Mater Interfaces; 2022 Jul; 14(28):31634-31644. PubMed ID: 35817627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual Functions of Riboflavin-functionalized Poly(lactic-co-glycolic acid) Nanoparticles for Enhanced Drug Delivery Efficiency and Photodynamic Therapy in Triple-negative Breast Cancer Cells.
    Mekseriwattana W; Phungsom A; Sawasdee K; Wongwienkham P; Kuhakarn C; Chaiyen P; Katewongsa KP
    Photochem Photobiol; 2021 Nov; 97(6):1548-1557. PubMed ID: 34109623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.
    Chadar R; Afsana ; Kesharwani P
    Int J Pharm; 2021 Aug; 605():120835. PubMed ID: 34197908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
    Bagalkot V; Gao X
    ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer.
    Nakhjavani M; Shigdar S
    Pharmacol Res; 2022 Jan; 175():106019. PubMed ID: 34861397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.
    Parvani JG; Jackson MW
    Endocr Relat Cancer; 2017 Apr; 24(4):R81-R97. PubMed ID: 28148541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
    Yang Z; Liu T; Xie Y; Sun Z; Liu H; Lin J; Liu C; Mao ZW; Nie S
    Acta Biomater; 2015 Oct; 25():194-204. PubMed ID: 26193000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.
    Liu X; Zhang G; Yu T; Liu J; Chai X; Yin D; Zhang C
    Int J Biol Macromol; 2023 Oct; 250():126147. PubMed ID: 37544559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
    Peng F; Xiong L; Peng C
    Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
    Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
    J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
    Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
    Front Immunol; 2022; 13():830606. PubMed ID: 35935985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
    Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
    ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.